Insulin glargine’s continued predominance, relative to newer insulins, may be due to several factors, including clinical inertia, which has been commonly described in the treatment of patients with type 2 diabetes.25 In addition, expert guidelines note that analog basal insulins, including insulin glargine, are associated with less hypoglycemia compared with NPH (isophane) human insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.